Gastroenterology
Volume 134, Issue 5 , Pages 1352-1359 , May 2008

Terlipressin and Albumin vs Albumin in Patients With Cirrhosis and Hepatorenal Syndrome: A Randomized Study

  • Marta Martín–Llahí

      Affiliations

    • Liver Unit, Hospital Clínic, University of Barcelona School of Medicine, Institut d'Investigacions Biomèdiques August Pi-Sunyer (IDIBAPS), Centro de Investigacíon Biomedica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Barcelona, Spain
    • ,
  • Marie–Noëlle Pépin

      Affiliations

    • Liver Unit, Hospital Clínic, University of Barcelona School of Medicine, Institut d'Investigacions Biomèdiques August Pi-Sunyer (IDIBAPS), Centro de Investigacíon Biomedica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Barcelona, Spain
    • ,
  • Mónica Guevara

      Affiliations

    • Liver Unit, Hospital Clínic, University of Barcelona School of Medicine, Institut d'Investigacions Biomèdiques August Pi-Sunyer (IDIBAPS), Centro de Investigacíon Biomedica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Barcelona, Spain
    • ,
  • Fernando Díaz

      Affiliations

    • Hospital Universitario Puerta del Mar, Cádiz, Spain
    • ,
  • Aldo Torre

      Affiliations

    • Liver Unit, Hospital Clínic, University of Barcelona School of Medicine, Institut d'Investigacions Biomèdiques August Pi-Sunyer (IDIBAPS), Centro de Investigacíon Biomedica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Barcelona, Spain
    • ,
  • Alberto Monescillo

      Affiliations

    • Hospital Universitario Insular, Las Palmas de Gran Canaria, Spain
    • ,
  • Germán Soriano

      Affiliations

    • Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
    • ,
  • Carlos Terra

      Affiliations

    • Liver Unit, Hospital Clínic, University of Barcelona School of Medicine, Institut d'Investigacions Biomèdiques August Pi-Sunyer (IDIBAPS), Centro de Investigacíon Biomedica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Barcelona, Spain
    • ,
  • Emilio Fábrega

      Affiliations

    • Hospital Universitario Marqués de Valdecilla, Santander, Spain
    • ,
  • Vicente Arroyo

      Affiliations

    • Liver Unit, Hospital Clínic, University of Barcelona School of Medicine, Institut d'Investigacions Biomèdiques August Pi-Sunyer (IDIBAPS), Centro de Investigacíon Biomedica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Barcelona, Spain
    • ,
  • Juan Rodés

      Affiliations

    • Liver Unit, Hospital Clínic, University of Barcelona School of Medicine, Institut d'Investigacions Biomèdiques August Pi-Sunyer (IDIBAPS), Centro de Investigacíon Biomedica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Barcelona, Spain
    • ,
  • Pere Ginès

      Affiliations

    • Liver Unit, Hospital Clínic, University of Barcelona School of Medicine, Institut d'Investigacions Biomèdiques August Pi-Sunyer (IDIBAPS), Centro de Investigacíon Biomedica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Barcelona, Spain
    • Corresponding Author InformationAddress requests for reprints to: Pere Ginès, MD, Liver Unit, Hospital Clínic, Villarroel, 170, Barcelona 08036, Spain.
    • ,
  • TAHRS Investigators

Received 6 September 2007 ,Accepted 24 January 2008.

References 

  1. Arroyo V, Gines P, Gerbes AL, et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis (International Ascites Club). Hepatology. 1996;23:164–176
  2. Gines P, Guevara M, Arroyo V, et al. Hepatorenal syndrome. Lancet. 2003;362:1819–1827
  3. Nair S, Verma S, Thuluvath PJ. Pretransplant renal function predicts survival in patients undergoing orthotopic liver transplantation. Hepatology. 2002;35:1179–1185
  4. Davis CL. Kidney failure in liver transplantation: it is time for action. Am J Transplant. 2006;6:2533–2534
  5. Gonwa TA, McBride MA, Anderson K, et al. Continued influence of preoperative renal function on outcome of orthotopic liver transplant (OLTX) in the US: where will MELD lead us?. Am J Transplant. 2006;6:2651–2659
  6. Moreau R, Lebrec D. Acute renal failure in patients with cirrhosis: perspectives in the age of MELD. Hepatology. 2003;37:233–243
  7. Salerno F, Gerbes A, Gines P, et al. Diagnosis, prevention and treatment of the hepatorenal syndrome in cirrhosis (A consensus workshop of the International Ascites Club). Gut. 2007;56:1310–1318
  8. Martin PY, Gines P, Schrier RW. Mechanisms of disease—nitric oxide as a mediator of hemodynamic abnormalities and sodium and water retention in cirrhosis. N Engl J Med. 1998;339:533–541
  9. Guevara M, Gines P, Fernandez-Esparrach G, et al. Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma volume expansion. Hepatology. 1998;27:35–41
  10. Gulberg V, Bilzer M, Gerbes AL. Long-term therapy and retreatment of hepatorenal syndrome type 1 with ornipressin and dopamine. Hepatology. 1999;30:870–875
  11. Uriz J, Gines P, Cardenas A, et al. Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenal syndrome. J Hepatol. 2000;33:43–48
  12. Moreau R, Durand F, Poynard T, et al. Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter study. Gastroenterology. 2002;122:923–930
  13. Gines P, Guevara M. Good news for hepatorenal syndrome. Hepatology. 2002;36:504–506
  14. Ortega R, Gines P, Uriz J, et al. Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study. Hepatology. 2002;36:941–948
  15. Bone RC, Balk RA, Cerra FB, et al. American-College of Chest Physicians Society of Critical Care Medicine Consensus Conference (Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis). Crit Care Med. 1992;20:864–874
  16. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334:693–699
  17. Solanki P, Chawla A, Garg R, et al. Beneficial effects of terlipressin in hepatorenal syndrome: a prospective, randomized placebo-controlled clinical trial. J Gastroenterol Hepatol. 2003;18:152–156
  18. Cardenas A, Gines P. Management of complications of cirrhosis in patients awaiting liver transplantation. J Hepatol. 2005;42:S124–S133
  19. Linas SL, Schaefer JW, Moore EE, et al. Peritoneovenous shunt in the management of the hepatorenal syndrome. Kidney Int. 1986;30:736–740
  20. Gines A, Escorsell A, Gines P, et al. Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites. Gastroenterology. 1993;105:229–236
  21. Ruiz-Del-Arbol L, Urman J, Fernandez J, et al. Systemic, renal, and hepatic hemodynamic derangement in cirrhotic patients with spontaneous bacterial peritonitis. Hepatology. 2003;38:1210–1218
  22. Ruiz-Del-Arbol L, Monescillo A, Arocena C, et al. Circulatory function and hepatorenal syndrome in cirrhosis. Hepatology. 2005;42:439–447
  23. Lee SS, Liu H. Cardiovascular determinants of survival in cirrhosis. Gut. 2007;56:746–748
  24. Quinlan GJ, Martin GS, Evans TW. Albumin: biochemical properties and therapeutic potential. Hepatology. 2005;41:1211–1219
  25. Sort P, Navasa M, Arroyo V, et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med. 1999;341:403–409
  26. Mitzner SR, Stange J, Klammt S, et al. Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: results of a prospective, randomized, controlled clinical trial. Liver Transpl. 2000;6:277–286
  27. Hassanein TI, Tofteng F, Brown RS, et al. Randomized controlled study of extracorporeal albumin dialysis for hepatic encephalopathy in advanced cirrhosis. Hepatology. 2007;46:1853–1862
  28. Romanelli RG, La Villa G, Barletta G, et al. Long-term albumin infusion improves survival in patients with cirrhosis and ascites: an unblinded randomized trial. World J Gastroenterol. 2006;12:1403–1407
  29. Jalan R, Mookerjee R, Cheshire L, et al. Albumin infusion for severe hyponatremia in patients with refractory ascites: a randomized clinical trial. J Hepatol. 2007;46(Suppl 1):
  30. Escorsell A, Del Arbol LR, Planas R, et al. Multicenter randomized controlled trial of terlipressin versus sclerotherapy in the treatment of acute variceal bleeding: The TEST study. Hepatology. 2000;32:471–476

 Supported by grants from Fundació Marató TV3 (2000.TV.2710-0) and Ministerio de Educación y Ciencia (SAF 2001/0300) and Instituto Reina Sofia de Investigación Nefrologia; a grant from the Fundación Banco de Bilbao-Vizcaya-Argentaria (FBBVA; to M.M-L.); a grant from the Fondation du Centre Hospitalier de l'Université de Montréal (CHUM; to M-N.P.); and a grant from Fondo de Investigación Sanitaria (FIS 01/3045; to M.G.). Ciberehd is funded by the Instituto de Salud Carlos III.

 Financial disclosures and conflicts of interest: Pere Ginès has received research support and lecture fees from Ferring Pharmaceuticals and research support from Orphan Therapeutics. Mónica Guevara has received lecture fees from Ferring Pharmaceuticals. The remaining authors have no conflicts of interest.

 M.M-L. and M-N.P. contributed equally to this work.

PII: S0016-5085(08)00252-7

doi: 10.1053/j.gastro.2008.02.024

Gastroenterology
Volume 134, Issue 5 , Pages 1352-1359 , May 2008

Article Tools

* Image Usage & Resolution